Physician profile
Keith D Carter
NPI 1942201082
$54,020.41
in general payments reported to CMS, 2019-2025
8 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $7,865 · 2021: $7,865 · 2022: $3,812 · 2023: $13K · 2024: $21K · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Travel and Lodging: $11K · Food and Beverage: $1,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,025.00 |
| Travel and Lodging | $11,178.85 |
| Food and Beverage | $1,687.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $43,937.72 | 2020-2024 | |
| Genentech USA, INC. | $9,141.25 | 2019-2025 | |
| F. Hoffmann-La Roche Ag | $549.21 | 2024 | |
| Sun Pharmaceutical Industries INC. | $150.00 | 2024 | |
| Alcon Vision LLC | $107.61 | 2022-2023 | Centurion |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.82 | 2019 | |
| Ani Pharmaceuticals, INC. | $38.18 | 2025 | Purified Cortrophin Gel |
| Edwards Lifesciences Corporation | $34.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.